Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Protocol: LB01B; LB02E
#M4

______________________________________________________________________________

| 390 | *** Abrogată |

|_______|______________________________________________________________________|
______________________________________________________________________________

| 391 | *** Abrogată |

|_______|______________________________________________________________________|
#B

______________________________________________________________________________

| 392 |J05AB04| RIBAVIRINUM**** | Protocol: J002N |

|_______|_______|____________________________________________|_________________|

________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB04 RIBAVIRINUM CAPS. 200 mg

REBETOL 200 mg 200 mg SP EUROPE
J05AB04 RIBAVIRINUM COMPR. FILM. 200 mg

COPEGUS(R) 200 mg ROCHE ROMANIA SRL

________________________________________________________________________________
______________________________________________________________________________

| 393 |J05AF05| LAMIVUDINUM**** | Protocol: J005N |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AF05 LAMIVUDINUM COMPR. FILM. 100 mg

ZEFFIX 100 mg 100 mg GLAXO GROUP LTD.
J05AF05 LAMIVUDINUM SOL. ORALĂ 10 mg/ml

EPIVIR 10 mg/ml 10 mg/ml GLAXO GROUP LTD.

J05AF05 LAMIVUDINUM COMPR. FILM. 150 mg

EPIVIR 150 mg 150 mg GLAXO GROUP LTD.

J05AF05 LAMIVUDINUM SOL. ORALĂ 5 mg/ml

ZEFFIX 5 mg/ml 5 mg/ml GLAXO GROUP LTD.

________________________________________________________________________________
______________________________________________________________________________

| 395 |J05AF10| ENTECAVIRUM**** | Protocol: J008N |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AF10 ENTECAVIRUM COMPR. FILM. 0,5 mg

BARACLUDE 0,5 mg 0,5 mg BRISTOL-MYERS SQUIBB

PHARMA EEIG

J05AF10 ENTECAVIRUM COMPR. FILM. 1 mg

BARACLUDE 1 mg 1 mg BRISTOL-MYERS SQUIBB

PHARMA EEIG

________________________________________________________________________________

______________________________________________________________________________

| 396 |L03AA02| FILGRASTIMUM (G-CSF)** | Protocol: B013K |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml

NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 48 MU/0.5 ml

NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V.

________________________________________________________________________________
______________________________________________________________________________

| 397 |L03AB04| INTERFERONUM ALFA 2a**** | Protocol: J007N |

|_______|_______|____________________________________________|_________________|
Tratamentul cu interferon alfa a fost asociat cu depresie şi suicid la unii pacienţi. Pacienţii cu istoric de ideaţie suicidară sau boală depresivă trebuie avertizaţi de riscuri. Trebuie monitorizat statusul psihiatric în timpul tratamentului.